Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome characterized by left ventricular diastolic dysfunction, elevated filling pressures, and normal ejection fraction (left ventricular ejection fraction ≥50%) in the absence of an underlying disease process. Its prevalence is increasing, driven by an aging population and rising comorbidities including obesity, diabetes, and hypertension. Given the benefit of emerging HFpEF therapies, such as glucagon-like peptide-1 inhibitors, early and accurate diagnosis is critical to improve outcomes. The diagnosis of HFpEF, however, can be challenging to make, and clinical practice relies heavily on echocardiographic evidence of diastolic dysfunction. There is a need for additional noninvasive diagnostic strategies to facilitate earlier HFpEF diagnosis to improve clinical outcomes. Emerging evidence suggests that cardiac magnetic resonance (CMR) imaging may have clinical value in enhancing HFpEF diagnosis and prognosis. Moreover, CMR tissue characterization by parametric mapping sequences (T1/T2 mapping and extracellular volume quantification) makes CMR a powerful tool for evaluating HFpEF mimickers, specific diseases that cause the clinical syndrome of heart failure in the setting of normal ejection fraction, which may confound HFpEF diagnosis. Finally, novel imaging sequences, such as magnetic resonance spectroscopy, diffusion tensor imaging, and elastography, are being developed to characterize metabolism and hemodynamics in vivo and may provide insight into HFpEF pathophysiology. The diagnostic and prognostic values of CMR-derived indices of diastolic dysfunction and the use of CMR to distinguish between HFpEF and its mimickers, as well as the use of novel CMR sequences in HFpEF, are reviewed herein.

Hypertrophic cardiomyopathy (HCM) is a naturally occurring cardiac disorder afflicting humans, cats, rhesus macaques, pigs, and rarely dogs. The disease is characterized by maladaptive left ventricular wall thickening. Over 1500 sarcomere-coding mutations explain HCM in humans, whereas only 3 have been reported in cat breeds. To date, no mutations have been described in dogs. HCM in a nuclear family of Golden Retrievers was identified following the sudden cardiac death of 3 related puppies <2 years of age from 2 dam-offspring repeat matings.

Surgery is an essential treatment for selected patients with infective endocarditis (IE). Despite indications for surgery, not all patients undergo surgery. Most previous IE cohorts have examined a selected group of patients from primary tertiary centers. Thus, the aims of this study were to describe the use of surgery by indication and to assess mortality in a nationwide cohort of patients with left-sided IE.

Inflammatory, myocarditis-like episodes precede and are associated with higher risk of sustained ventricular arrhythmias and heart failure in patients with pathogenic or likely pathogenic desmoplakin (DSP) variants. Whether the recurrence and treatment of myocarditis-like episodes influence the outcomes in this population is unknown. This study aimed to assess the prognostic impact of the recurrence and treatment of myocarditis-like episodes in patients with pathogenic or likely pathogenic DSP variants.

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have shown beneficial effects in heart failure (HF) management, but data on their use in geriatric populations with high comorbidity remain limited. This observational study aimed to assess the real-world efficacy and safety of SGLT2i in elderly patients with HF.

Sarcopenia is associated with adverse outcomes in patients with end-stage heart failure. Muscle mass can be quantified via manual segmentation of computed tomography images, but this approach is time-consuming and subject to interobserver variability. We sought to determine whether fully automated assessment of radiographic sarcopenia by deep learning would predict heart transplantation outcomes.

The 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America guidelines introduced elevated natriuretic peptide (NP) levels as a criterion for defining stage B heart failure (HF), or pre-HF, to identify individuals at greatest risk for future HF. Given the known NP deficiency in obesity, we aimed to assess whether a single NP cut point would disproportionately up-classify individuals with versus without obesity to stage B HF.

Socioeconomic inequities in access to heart transplantation, including those based on insurance coverage and race or ethnicity, are well documented. During the COVID pandemic, the federal government declared a Public Health Emergency (PHE), which prevented states from disenrolling people from Medicaid. We sought to determine whether this policy was associated with changes in the insurance or racial composition of the heart transplant waiting list.

Digital remote patient monitoring (RPM), such as home-based blood pressure, heart rate, or weight monitoring, enables longitudinal care outside traditional health care settings, especially in the vulnerable period after hospitalizations, with broad coverage of the service by payers. We sought to evaluate patterns of RPM service availability at US hospitals and the characteristics of hospitals and the counties they serve that are associated with the availability of these services.

The Evoque system is the first commercially available transcatheter tricuspid valve replacement (TTVR) system in the United States. However, challenging anatomy in real-world patients could preclude successful transfemoral Evoque TTVR. We aim to investigate the feasibility of the transjugular Evoque TTVR in anatomy unsuitable for a transfemoral approach.